EP3126527A4 - Détermination de polymorphismes d'un seul nucléotide utiles pour prédire la réponse à la rasagiline - Google Patents

Détermination de polymorphismes d'un seul nucléotide utiles pour prédire la réponse à la rasagiline Download PDF

Info

Publication number
EP3126527A4
EP3126527A4 EP15773661.2A EP15773661A EP3126527A4 EP 3126527 A4 EP3126527 A4 EP 3126527A4 EP 15773661 A EP15773661 A EP 15773661A EP 3126527 A4 EP3126527 A4 EP 3126527A4
Authority
EP
European Patent Office
Prior art keywords
rasagiline
determination
single nucleotide
nucleotide polymorphisms
predict response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15773661.2A
Other languages
German (de)
English (en)
Other versions
EP3126527A1 (fr
Inventor
Mario MASELLIS
Joanne Knight
Maureen Shannon COLLINSON
Anthony Edward LANG
James Lowery Kennedy
Joseph Levy
Amir TCHELET
Iris Grossman
Eli Eyal
Barnett OFRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP3126527A1 publication Critical patent/EP3126527A1/fr
Publication of EP3126527A4 publication Critical patent/EP3126527A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP15773661.2A 2014-04-01 2015-03-31 Détermination de polymorphismes d'un seul nucléotide utiles pour prédire la réponse à la rasagiline Withdrawn EP3126527A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973603P 2014-04-01 2014-04-01
PCT/US2015/023618 WO2015153629A1 (fr) 2014-04-01 2015-03-31 Détermination de polymorphismes d'un seul nucléotide utiles pour prédire la réponse à la rasagiline

Publications (2)

Publication Number Publication Date
EP3126527A1 EP3126527A1 (fr) 2017-02-08
EP3126527A4 true EP3126527A4 (fr) 2017-10-04

Family

ID=54189487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15773661.2A Withdrawn EP3126527A4 (fr) 2014-04-01 2015-03-31 Détermination de polymorphismes d'un seul nucléotide utiles pour prédire la réponse à la rasagiline

Country Status (9)

Country Link
US (1) US20150275302A1 (fr)
EP (1) EP3126527A4 (fr)
JP (1) JP2017517481A (fr)
AR (1) AR099950A1 (fr)
CA (1) CA2943841A1 (fr)
IL (1) IL247824A0 (fr)
MX (1) MX2016012718A (fr)
TW (1) TW201621051A (fr)
WO (1) WO2015153629A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087735A1 (fr) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Procédé de traitement de la maladie de crohn
CN107941953A (zh) * 2017-11-30 2018-04-20 天津生机集团股份有限公司 一种兽药中金刚烷胺药物残留的检测方法
CN109825572A (zh) * 2019-03-13 2019-05-31 陈向东 一种检测与异丙酚的敏感性相关基因多态性的试剂盒及其检测方法
CN118406755B (zh) * 2024-07-02 2024-09-10 解码(上海)生物医药科技有限公司 一种指导帕金森病用药的基因多态性检测引物组及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631675A1 (fr) * 2005-11-30 2007-06-21 The University Of North Carolina At Chapel Hill Identification de variants polymorphiques genetiques associes aux troubles somatosensoriels et procedes d'utilisation de ces derniers
WO2008017002A2 (fr) * 2006-08-01 2008-02-07 The Ohio State University Research Foundation Polymorphismes dans des gènes affectant des troubles du système nerveux central et leurs utilisations
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
EP2406396A2 (fr) * 2009-03-12 2012-01-18 Brainco Biopharma, S.L. Outil de génotypage pour améliorer le pronostic et la gestion clinique de patients atteints de sclérose en plaques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOSÉ A G AGÚNDEZ ET AL: "Anti-Parkinson's disease drugs and pharmacogenetic considerations", EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, vol. 9, no. 7, 9 April 2013 (2013-04-09), GB, pages 859 - 874, XP055399975, ISSN: 1742-5255, DOI: 10.1517/17425255.2013.789018 *
OLIVIER RASCOL: "A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecifi ed and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes", 7 April 2011 (2011-04-07), XP055046322, Retrieved from the Internet <URL:http://ac.els-cdn.com/S1474442211700734/1-s2.0-S1474442211700734-main.pdf?_tid=ce3cf428-3d3e-11e2-af06-00000aab0f01&acdnat=1354535253_379ce207ffa1d143f20b3614e9683135> [retrieved on 20121203], DOI: 10.1016/S1474- *
See also references of WO2015153629A1 *

Also Published As

Publication number Publication date
TW201621051A (zh) 2016-06-16
WO2015153629A1 (fr) 2015-10-08
JP2017517481A (ja) 2017-06-29
CA2943841A1 (fr) 2015-10-08
EP3126527A1 (fr) 2017-02-08
US20150275302A1 (en) 2015-10-01
IL247824A0 (en) 2016-11-30
AR099950A1 (es) 2016-08-31
MX2016012718A (es) 2016-12-16

Similar Documents

Publication Publication Date Title
EP3194411A4 (fr) Analogues nucléotidiques
ZA201701246B (en) Synthesis of dna
EP3160979A4 (fr) Procédés de préparation d&#39;analogues nucléotidiques substitués
EP3140427A4 (fr) Biomarqueurs utilisables pour évaluer la réponse aux inhibiteurs de la pi3k
EP3134550A4 (fr) Détermination de structure à haut rendement à l&#39;aide de calibres d&#39;acides nucléiques
GB2591198B (en) Biochemical reaction system
EP3230472A4 (fr) Méthodes et matériaux permettant de prédire une réaction au niraparib
EP3240910A4 (fr) Pcr quantitative multiplex
EP3377658A4 (fr) Réactifs nucléotidiques modifiés
EP3189206A4 (fr) Adjonction de réactifs à base d&#39;aluminium à des flux d&#39;eau contenant des oxyanions
ZA201608555B (en) Biomarkers for response to ezh2 inhibitors
EP3176269A4 (fr) Nouveau biomarqueur permettant de prédire la sensibilité à l&#39;inhibiteur de met et son utilisation
IL247824A0 (en) Single nucleotide polymorphism characterization for predicting response to rasagiline
EP3204469A4 (fr) Procédé de purification d&#39;une composition organique
GB201400522D0 (en) Nucleosome substrate assays
EP3095867A4 (fr) Acide nucléique inhibant l&#39;expression de bêta2gpi
EP3058107A4 (fr) Polymorphisme d&#39;un seul nucléotide du complexe majeur d&#39;histocompatibilité
HK1228468A1 (en) Determination of single nucleotide polymorphisms useful to predict response for rasagiline
GB2594163B (en) Biochemical reaction system
HK1260665A1 (en) Methods for predicting response to anti-tnf therapy
HK1230671A1 (en) Biomarkers for response to ezh2 inhibitors
GB2592541B (en) Biochemical reaction system
EP3259355A4 (fr) Procédés associés au séquençage de l&#39;adn
HK1236571A (zh) 聚合酶
AU2014901299A0 (en) Substrates for water purification

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: COLLINSON, MAUREEN, SHANNON

Inventor name: TCHELET, AMIR

Inventor name: GROSSMAN, IRIS

Inventor name: KNIGHT, JOANNE

Inventor name: MASELLIS, MARIO

Inventor name: OFRA, BARNETT

Inventor name: EYAL, ELI

Inventor name: LEVY, JOSEPH

Inventor name: LANG, ANTHONY, EDWARD

Inventor name: KENNEDY, JAMES, LOWERY

DAV Request for validation of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170901

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4985 20060101ALI20170828BHEP

Ipc: A61P 25/16 20060101ALI20170828BHEP

Ipc: A61K 31/135 20060101ALI20170828BHEP

Ipc: A61K 31/4045 20060101ALI20170828BHEP

Ipc: A61K 31/428 20060101ALI20170828BHEP

Ipc: A61K 31/381 20060101ALI20170828BHEP

Ipc: A61K 31/48 20060101ALI20170828BHEP

Ipc: A61K 31/198 20060101ALI20170828BHEP

Ipc: A61K 31/439 20060101ALI20170828BHEP

Ipc: C12Q 1/68 20060101AFI20170828BHEP

Ipc: A61K 45/06 20060101ALI20170828BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1228468

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180330

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1228468

Country of ref document: HK